NCT05319873 - Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2027

Conditions

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaLocally Advanced HER2-Positive Breast CarcinomaMetastatic HER2-Positive Breast CarcinomaPrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8

Interventions

DRUG

Carboplatin

Given IV

DRUG

Docetaxel

Given IV

DRUG

Fulvestrant

Given SC

BIOLOGICAL

Pertuzumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary Studies

DRUG

Ribociclib

Given PO

BIOLOGICAL

Trastuzumab

Given IV

DRUG

Tucatinib

Given PO

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles